20th Anniversary · 1999 - 2019

May 11, 2016: ”Pharma, Science, and Innovation: What Does the Future Hold for the Health Care Industry and for Patients?”

  1. Jerry Avorn, The First Amendment and Pharmaceutical Promotion, Health Affairs Blog, March 11, 2016
  2. Tufts Center for the Study of Drug Development, Tufts CSDD Assessment of Cost to Develop and Win Marketing Approval for a New Drug Now Published, Press Release, March 10, 2016
  3. PhRMA (Pharmaceutical Research and Manufacturers of America), Policy Solutions:  Delivering Innovative Treatments to Patients, March 2016
  4. PhRMA (Pharmaceutical Research and Manufacturers of America), Prescription Medicines: Costs in Context, 2016
  5. Jonathan J. Darrow, Jerry Avorn, & Aaron S. Kesselheim, New FDA Breakthrough-Drug Category – Implications for Patients, New Engl J Med 2014;370:1252-62 & 371:87-90
  6. Aaron S. Kesselheim, et al., Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study, BMJ 2015; 351:h4633
  7. Aaron S. Kesselheim, et al., The Roles of Academic, Rare Diseases, and Repurposing in the Development of the Most Transformative Drugs, HEALTH AFFAIRS 34, NO. 2 (2015): 286–293
  8. Jerry Avorn & Aaron S. Kesselheim, Perspective, The 21st Century Cures Act – Will It Take Us Back in Time?, New Engl J Med 2015;372:2473-5 & 373:1677-80
  9. Aaron S. Kesselheim, et al., Characteristics of Clinical Trials to Support Approval of Orphan vs. Nonorphan Drugs for Cancer, JAMA.2011;305(22):2320-2326